Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

INTRODUCTION: Kawasaki disease (KD) is an acute, self-limited vasculitis of unknown aetiology that predominantly affects infants and young children. We hypothesise that cyclosporin A (CsA) may be effective in treating KD by regulating the Ca(2+)/NFAT signalling pathway. This trial compares the curre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Aoyagi, Reiko, Hamada, Hiromichi, Sato, Yasunori, Suzuki, Hiroyuki, Onouchi, Yoshihiro, Ebata, Ryota, Nagashima, Kengo, Terauchi, Moe, Terai, Masaru, Hanaoka, Hideki, Hata, Akira
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2015
Matèries:
Paediatrics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4679944/
https://ncbi.nlm.nih.gov/pubmed/26628527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-009562
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars